Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma

NCT06989437 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06989437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06989437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
Pfizer
Phase
Phase 2/3
Overall status
Recruiting
Start date
October 3, 2025
Completion date
December 24, 2029
Enrollment
982 (estimated)
Sites
230

Conditions

As the registry lists them; a condition with its own page is linked.

cachexia, metastatic pancreatic ductal adenocarcinoma